Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts.
Imiquimod (IQ) has been successfully used in treatment of genital warts. In clinical settings, patients responded well but wart reduction rates varied. Our aim was to find a correlation between clinical responses and pretreatment (constitutive) levels of genes that might be involved in the molecular action of IQ. Since IQ is a cytokine inducer, we analyzed levels of expression of genes of the JAK/STAT signaling pathway and their inhibitors as well as interferon response factors (IRFs) in pretreatment biopsy specimens from complete responders (99 to 100% wart reduction rate) versus incomplete responders (75 to 92% wart reduction rate) by reverse transcription-PCR. We found that mRNA levels of signal transducer and activator of transcription 1 (STAT1) and IRF1 were higher in complete responders than in incomplete responders. Incomplete responders expressed larger amounts of STAT3, IRF2, and protein inhibitor of activated STAT1 (PIAS1) mRNAs compared to complete responders before IQ treatment. We hypothesize that high-level expression of STAT1 and IRF1 is advantageous for a better IQ response. The observed differences in constitutive mRNA levels of these genes may be the consequence of alterations in cellular differentiation and/or variable expression of endogenous interferons. Previous in vitro studies showed that keratinocyte differentiation coordinates the balance between positive and negative signals along the JAK/STAT pathway by regulating the IRF1:IRF2 and STAT1:PIAS1 ratios and thus affecting induction of IQ-inducible genes. Specifically, differentiation supports constitutive expression of STAT1 and IRF1 mRNAs but not expression of IRF2 and PIAS1. Our data are in good agreement with studies that showed the importance of STAT1 in cytokine induction and activation of interferon-responsive genes by IQ.
Arany
I
I
Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA. iarany@utmb.edu
Tyring
S K
SK
Brysk
M M
MM
Stanley
M A
MA
Tomai
M A
MA
Miller
R L
RL
Smith
M H
MH
McDermott
D J
DJ
Slade
H B
HB
D000634:Aminoquinolines / Q000494:pharmacology* / Q000627:therapeutic use; D001706:Biopsy; D002454:Cell Differentiation / Q000187:drug effects; D003218:Condylomata Acuminata / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D004311:Double-Blind Method; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D000077271:Imiquimod; D007369:Interferon Inducers / Q000494:pharmacology* / Q000627:therapeutic use; D007372:Interferons / Q000235:genetics / Q000378:metabolism; D015603:Keratinocytes / Q000187:drug effects / Q000502:physiology; D050828:Protein Inhibitors of Activated STAT; D011506:Proteins / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D050794:STAT1 Transcription Factor; D050796:STAT3 Transcription Factor; D015534:Trans-Activators / Q000235:genetics* / Q000378:metabolism
D000634:Aminoquinolines; D004268:DNA-Binding Proteins; D007369:Interferon Inducers; D050828:Protein Inhibitors of Activated STAT; D011506:Proteins; D012333:RNA, Messenger; D050794:STAT1 Transcription Factor; C494079:STAT1 protein, human; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D015534:Trans-Activators; D007372:Interferons; D000077271:Imiquimod